Michael Williams headshot

Michael E. Williams

Byrd S. Leavell Professor of Medicine
Division Head, Hematology and Oncology
Unit: School of Medicine
Department: Department of Medicine, Hematology and Oncology
Office location and address
1335 Lee St
Charlottesville, Virginia 22903
Residency, Internal Medicine, University of Virginia
Clinical Fellowship, Hematology, University of Virginia
Clinical Fellowship, Oncology, University of Virginia
B.S., Botany, Ohio State University
S.M., Microbiology, Harvard University School of Public Health
M.D., Medicine, University of Cincinnati College of Medicine

Dr. Williams' research interests are in novel therapeutic approaches for non-Hodgkin lymphomas, mantle cell lymphoma and CLL, including targeted agents and immunotherapeutics. He serves on the scientific advisory boards of the Lymphoma Research Foundation and the European Mantle Cell Lymphoma Network, and is vice-chair of the Eastern Cooperative Group Lymphoma Core Committee. He also serves as chair of the Hematology Subspecialty Board of the American Board of Internal Medicine, and is an ABIM Council Member.

MD-INMD Phase 3 Study of the Bruton's Tyrosine kinase (BTK) Inhibitor Ibrutinib vs. Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Source: Pharmacyclics, Inc.
June 01, 2012 – April 10, 2019
Lenalidomide in Subjects with Mantle Cell Non-Hodgkin's Lymphoma
Source: Celgene Corporation
April 09, 2009 – October 01, 2017
A Randomized Phase II Trial to Compare the Efficacy of Two Doses of Fostamatinib Disodium
Source: SCRI Services, LLC
November 17, 2012 – November 17, 2016
Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Source: Gilead Sciences, Inc.
December 01, 2011 – June 30, 2016
MD-INMD Investigator Initiated Study to Evaluate the Long-Term Toxicity and Efficacy of Bendamustine in Patients with Non-Hodgkin Lymphoma Treated on Five Phase 2 Trials
Source: Cornell University
April 09, 2014 – April 08, 2016
Commonwealth Foundation for Cancer Research
Source: Commonwealth Cancer Foundation for Research
June 01, 2002 – December 31, 2015
MD-INMD-HO-WilliamsMCL4001-An Open-Label Treatment Use Protocol for Ibrutinib(PCI-32675)in Subjects with Relapsed or Refractory Mantle Cell Lymphoma
Source: Janssen Research & Development, LLC
October 28, 2013 – October 31, 2015
MD-INMD A Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituxmabochemotherapy
Source: Novartis Pharmaceuticals Corporation
April 28, 2010 – April 28, 2013
A Phase 2 Study of VELCADE (bortezomib) in Combination with Bendamustine & Rituximab
Source: Millennium Pharmaceuticals, Inc.
February 10, 2009 – February 09, 2013